Market Trends of Cryptococcosis Therapeutics Industry
This section covers the major market trends shaping the Cryptococcosis Therapeutics Market according to our research experts:
Flucytosine Segment is Expected to Hold a Significant Market Share
Flucytosine is a small, water-soluble molecule which is a nucleoside analog antifungal drug that acts by disrupting pyrimidine metabolism in the fungal cell nucleus. Flucytosine is generally given as first-line treatment in combination with other antifungal medications. Flucytosine was major revenue holding segment because it is given as first-line treatment in combination with other antifungal medications.
According to the United Nations Program on HIV/AIDS and the World Health Organization, globally approximately one million cases of cryptococcosis are reported each year resulting in 625,000 deaths approximately. The increasing prevalence of cryptococcosis and increasing new and advanced treatment opportunities are the key factors for the growth of the cryptococcosis market.
North America is Expected to Dominate the Market and Expected to do Same in the Forecast Period
North America is expected to hold a major share globally in cryptococcosis market due to the rising prevalence of cryptococcosis, the rise in technological advancements, and higher cost of medication in this region.
As per the study article published by National Institute of Health in 2019, in the United States prevalence of cryptococcosis is estimated to be about 0.4-1.3 cases per 100,000 population and 2-7 cases per 100,000 in people affected with AIDS with a case fatality ratio of about 12%. Therefore, North America holds a major market share due to the rising prevalence of cryptococcosis in the endemic areas that are fueling the growth of the overall regional market to a large extent.
